Literature DB >> 11745718

A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.

S M Khoo1, G A Edwards, C J Porter, W N Charman.   

Abstract

Postprandial administration of halofantrine (Hf), an important antimalarial, leads to 3- and 12-fold increases in oral bioavailability in humans and beagles, respectively, and corresponding 2.4-fold and 6.8-fold decreases in metabolic conversion to desbutylhalofantrine (Hfm). Factors contributing to the decreased postprandial metabolism of Hf could include inhibition of presystemic CYP3A metabolism by food components and/or recruitment of the intestinal lymphatics as an absorption pathway. Although previous rat studies confirmed Hf base is a substrate for lymphatic transport, it is difficult to extrapolate such data to higher species, as the largely constant bile flow in a rat precludes attainment of representative pre- and postprandial states, and formulations administered to rats are often not relevant to higher species. These limitations have now been addressed by development of a conscious dog model that allows simultaneous study of intestinal lymphatic and nonlymphatic drug absorption and aspects of enterocyte-based drug metabolism. After oral administration of 100 mg Hf base, the mean fasted and postprandial lymphatic transport was 1.3% and 54% of the administered dose, respectively. Comparison of portal and systemic plasma Hfm concentration profiles suggested enterocyte-based conversion of Hf to Hfm; however, the proportion of Hf metabolized to Hfm was similar after fasted or postprandial administration. Hence, it appears that the previously observed decrease in the postprandial metabolism of Hf is largely a consequence of significant postprandial intestinal lymphatic transport (which bypasses first pass hepatic metabolism). This new dog model will facilitate identification of the key factors that impact bioavailability, lymphatic transport, and metabolic profiles of highly lipophilic drugs. Copyright 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90:1599-1607, 2001

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745718     DOI: 10.1002/jps.1110

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism.

Authors:  Natalie L Trevaskis; David M Shackleford; William N Charman; Glenn A Edwards; Anne Gardin; Silke Appel-Dingemanse; Olivier Kretz; Bruno Galli; Christopher J H Porter
Journal:  Pharm Res       Date:  2009-03-12       Impact factor: 4.200

2.  A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Authors:  Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

3.  The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport.

Authors:  Natalie L Trevaskis; Luojuan Hu; Suzanne M Caliph; Sifei Han; Christopher J H Porter
Journal:  J Vis Exp       Date:  2015-03-06       Impact factor: 1.355

Review 4.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

5.  Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats.

Authors:  Mette Grove; Jeanet L Nielsen; Gitte P Pedersen; Anette Müllertz
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.200

6.  Bile increases intestinal lymphatic drug transport in the fasted rat.

Authors:  Natalie L Trevaskis; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

7.  Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies.

Authors:  Emma Lawless; Brendan T Griffin; Aoife O'Mahony; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2014-11-27       Impact factor: 4.200

Review 8.  Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.

Authors:  Oljora Rezhdo; Lauren Speciner; Rebecca Carrier
Journal:  J Control Release       Date:  2016-08-09       Impact factor: 9.776

9.  Enhancement of oral moxidectin bioavailability in rabbits by lipid co-administration.

Authors:  Mohamad Firas Bassissi; Anne Lespine; Michel Alvinerie
Journal:  Parasitol Res       Date:  2004-08-26       Impact factor: 2.289

10.  Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.

Authors:  Shui-Mei Khoo; David M Shackleford; Christopher J H Porter; Glenn A Edwards; William N Charman
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.